State Key Laboratory in Oncology in South China, Department of Clinical Oncology, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Br J Cancer. 2011 Mar 15;104(6):1000-6. doi: 10.1038/bjc.2011.32. Epub 2011 Mar 1.
Our recent work has shown the feasibility of using a refined immunomagnetic enrichment (IE) assay to detect cytokeratin 20-positive circulating tumour cells (CK20 pCTCs) in colorectal cancer (CRC) patients. We attempted to improve the sensitivity for CRC by detecting another intestinal-type differentiation marker, CDX2 pCTCs, using the same methodology.
CDX2 pCTCs were detected in patients with CRC, colorectal adenoma (CAD), benign colorectal diseases (BCD), other common cancers (OCC) and normal subjects (NS). Statistical analysis was used to correlate CDX2 pCTCs to the clinicohistopathological factors, recurrence, metastasis and survival after follow-up for 42 months in CRC patients.
CDX2 pCTCs were detected in 81% CRC patients (73 out of 90, median number=21.5 CTCs), 7.5% CAD patients (3 out of 40), 0% patients with BCD (0 out of 90), 2.5% patients with OCC (2 out of 80) and 0% NS (0 out of 40). Furthermore, statistical analysis showed that CDX2 pCTC numbers were associated with tumour- node-metastasis stage and lymph node status. Using the median CDX2 pCTC numbers as the cutoff points, stratified groups of CRC patients had significant differences in their recurrence and survival.
This study showed that the refined IE assay can detect CDX2 pCTCs with high sensitivity and that CDX2 pCTCs can generate clinically important information for CRC patients.
我们最近的工作表明，使用改良的免疫磁珠富集（IE）检测方法检测结直肠癌（CRC）患者中细胞角蛋白 20 阳性循环肿瘤细胞（CK20 pCTCs）是可行的。我们试图通过使用相同的方法检测另一种肠型分化标志物 CDX2 pCTCs 来提高对 CRC 的检测灵敏度。
检测 CRC、结直肠腺瘤（CAD）、良性结直肠疾病（BCD）、其他常见癌症（OCC）和正常对照（NS）患者中的 CDX2 pCTCs。统计分析用于将 CDX2 pCTCs 与 CRC 患者的临床病理因素、复发、转移和随访 42 个月后的生存相关联。
在 90 例 CRC 患者（73 例，中位数=21.5 个 CTCs）、40 例 CAD 患者（7.5%）、90 例 BCD 患者（0%）、80 例 OCC 患者（2.5%）和 40 例 NS 患者（0%）中检测到 CDX2 pCTCs。此外，统计分析表明 CDX2 pCTC 数量与肿瘤-淋巴结-转移分期和淋巴结状态相关。使用中位数 CDX2 pCTC 数量作为截断点，CRC 患者的分层组在复发和生存方面存在显著差异。
本研究表明，改良的 IE 检测方法可以高灵敏度地检测 CDX2 pCTCs，CDX2 pCTCs 可为 CRC 患者提供具有临床重要意义的信息。
